Bristol-myers Squibb Compnay

Dade Behring Marburg Gmbh

Syntex (u.s.a.) Inc.

Thomas D Kempe

Mohan Srinivasan

Indrani Chakraborty

Paul O Sheppard

Scott R Presnell

Mark W Rixon

Josephine M Cardarelli

Edwin F Ullman

Mark J Selby

Alan J Korman

Nils Lonberg

Arvind Rajpal

Guodong Chen

Maria N Jure-Kunkel

Aaron Paul Yamniuk

Stanley Richard Krystek, Jr

Kent B Thudium

Han Chang

Alison Witte

Mark F Maurer

Xi-Tao Wang

Susan Wong

Marcel R Pirio

Karla Ann Henning

Brenda L Stevens

Michelle Minhua Han

Jochem Gokemeijer

Bryan C Barnhart

Alexander T Kozhich

Ming Lei

Hui Wei

Steven Sheriff

Michael Quigley

Lumelle A Schneeweis

Xiang Shao

Susan Chien-Szu Wong

Liang Schweizer

Sandra V Hatcher

Hadia Lemar

Christina Maria Milburn

Patrick Guirnalda

Zhehong Cai

Marie-Michelle Navarro Garcia

John Jelesko

Mary J Cerelli

Zheng Yang

Suzanna S Pedersen

Zafrira Avnur

Christine Huang

Yan Feng

Praveen Aanur

Nels B Hamacher

Maria Rodriguez

Susan C Wong

Stanley R Krystek

Mian Gao

Tracy Arakaki

Kateri Atkins

Thomas Edwards

Noah Ditto

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against OX-40 and uses thereof

Antibodies against OX40 and uses thereof

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies

Polynucleotides encoding IL-17/IL-23 bispecific, IL-17A/F and IL-23p19 antibodies

Bispecific antibodies to IL-23 and IL-17A/F

Receptors are disclosed that are antibodies that exhibit a binding affinity for an immune complex of a monoepitopic antigen and an antibody for such antigen that is substantially greater than the binding affinity for the monoepitopic antigen or the antibody for the monoepitopic antigen apart from the immune complex. Normally, the monoepitopic antigen has a molecular weight less than 1500 and is an organic compound. The antibodies of the present invention find use in a method for determining a monoepitopic antigen in a sample suspected of containing such antigen. The method comprises forming an immune sandwich complex comprising the monoepitopic antigen or an analog thereof, a first monoclonal antibody that binds to the monoepitopic antigen, and a second monoclonal antibody that is an antibody of the present invention and detecting the immune sandwich complex. Compositions of matter and kits for use in conducting an assay in accordance with the invention as well as methods for producing the above receptors are also disclosed.

Receptors for immune complexes

This invention relates to novel monoclonal antibodies XI-4G6, XII-10E3 and XII-3B2, which are capable of recognizing bone alkaline phosphatase and not liver alkaline phosphatase. Methods and kits for using these antibodies in the determination of bone alkaline phosphatase are also described.

Assay for bone alkaline phosphatase

Receptors are disclosed that are antibodies that exhibit a binding affinity for an immune complex of a monoepitopic antigen and an antibody for such antigen that is substantially greater than the binding affinity for the monoepitopic antigen or the antibody for the monoepitopic antigen apart from the immune complex. In one embodiment the receptors are antibodies prepared against an affinity-labeled complex of an antigen and an antibody for the antigen. Normally, the monoepitopic antigen has a molecular weight less than 1500 and is an organic compound. The antibodies of the present invention find use in a method for determining a monoepitopic antigen in a sample suspected of containing such antigen. The method comprises forming an immune sandwich complex comprising the monoepitopic antigen or an analog thereof, a first monoclonal antibody that binds to the monoepitopic antigen, and a second monoclonal antibody that is an antibody of the present invention and detecting the immune sandwich complex. Compositions of matter and kits for use in conducting an assay in accordance with the invention as well as methods for producing the above receptors are also disclosed.

Growing community of inventors

Sunnyvale, CA, United States of America

Thomas D Kempe